BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Policy

  Former Provectus CEO Used Company Cash for Restaurants, Cosmetic Surgery and More

  Craig Dees, CEO of Provectus treated the company as “his own personal piggy bank” by submitting hundreds of falsified records to obtain $3.2M for personal expenses

  December 13, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  How GlycoMimetics Defied a Hematology Biotech Pitfall While Its Peers Fell

  GlycoMimetics defied a hematology biotech pitfall Tuesday, breaking out on strong cancer-drug data as shares of Global Blood Therapeutics and Spark Therapeutics trended in the opposite direction.

  December 13, 2017

   · 

  1 min read
• Business

  BGI Genomics Forms $7.6M JV with TCM Company Kangmei

  Kangmei will supply the JV with 95% of the $7.6M in cash, while BGI will contribute the remaining 5% of the JV’s value with instruments and technology.

  December 13, 2017

   · 

  1 min read
• 

  Drug Development

  Besties Regeneron, Sanofi Show Off Phase II Skin Cancer Data

  The positive results are spurring the companies to begin seeking approval for the checkpoint inhibitor.

  December 13, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Biotech Bay

  Bay Area’s Pionyr Immunotherapeutics Scores $62M to Push Anti-Tumor Tech Towards Clinic

  Pionyr was founded in 2015 by a UCSF professor and a Genentech alum.

  December 13, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Teva to Unveil Job Cuts, Closing of Some Ops Thursday

  It seems those thousands of anticipated and dreaded pink slips at Teva will be handed out on Thursday.

  December 13, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Daichi Sankyo Abandons Deal With Nektar Therapeutics After Drug Tanks in Europe

  Daiichi Sankyo informed Nektar that it was terminating a collaboration and licensing deal, effective Feb. 4, 2018.

  December 13, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Genetown

  Why Bluebird Bio Investors Aren’t Singing the Blues

  bluebird bio stock has been on an upswing for most of the year, having recently taken a spike after positive news at the ASH Annual Meeting.

  December 13, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Pharm Country

  Why Pfizer’s 2017 Was Mediocre at Best

  Pfizer’s 2017 wasn’t horrible. Just ho-hum.

  December 13, 2017

   · 

  1 min read
• 

  Business

  Sanofi Exec Forced to Apologize During Dengue Vaccine Inquiry

  The French executive made the public apology after he was castigated by SAGIP Rep. Rodante Marcoleta for his company’s “insensitivity” to the concerns of the Filipino public.

  December 13, 2017

   · 

  1 min read